Table 1.
Characteristic proportion of 21 included studies.
| Characteristics | Summary statistics |
|---|---|
| No. of publications, n (%) | 21 (100%) |
| Animal species, n (%) | |
| Rat | 20 (94.7%) |
| Mouse | 1 (5.3%) |
| Animal gender, n (%) | |
| Male | 12 (57.2%) |
| Female | 7 (33.3%) |
| Unknown | 2 (9.5%) |
| Lesion model, n (%) | |
| 6-OHDA | 21 (100%) |
| NSPCs source specie, n (%) | |
| Allogeneic | 10 (47.6%) |
| Xonogeneic | 11 (52.4%) |
| NSPCs state, n (%) | |
| PC-NSPC | 17 (81.0%) |
| PSC-NSPC | 4 (19.0%) |
| Administration time postinjury, n (%) | |
| ≤2 week | 5 (23.8%) |
| ＞2 week | 16 (76.2%) |
| Administration site, n (%) | |
| Striatum | 15 (71.4%) |
| Substantia nigra | 6 (28.6%) |
| Cell dosage (cells/kg), median (Q1, Q3) | 1.5E+06 (5.0E+05, 2.5E+06) |
| Follow-up period (weeks), n (%) | |
| <12 weeks | 12 (57.2%) |
| ≥12 weeks | 9 (42.8%) |
| Immunosuppressant, n (%) | |
| No | 9 (42.8%) |
| Yes | 12 (57.2%) |
| Behavioral outcome, n (%) | |
| Amphetamine-induced rotation | 8 (38.1%) |
| Apomorphine-induced rotation | 11 (52.4%) |
| Limb function | 8 (38.1%) |
Abbreviations: 6-OHDA, 6-hydroxydopamine; PC-NSPC, primary cells-neural stem/progenitor cells; PSC-NSPC, pluripotent stem cell-neural stem/progenitor cells; Q1, first quartile; Q3, third quartile.